Immune response variation in mild and severe COVID-19 patients.

Samuel Stroz, Piotr Kosiorek, Edyta Zbroch, Bozena Mikoluc, Anna Stasiak-Barmuta
Author Information
  1. Samuel Stroz: Department of Clinical Immunology, Medical University of Bialystok, Bialystok, Poland Email: samuelstroz92@gmail.com.
  2. Piotr Kosiorek: Department of Clinical Immunology, Medical University of Bialystok, Bialystok, Poland Email: samuelstroz92@gmail.com.
  3. Edyta Zbroch: Department of Internal Medicine and Hypertension, Medical University of Bialystok, Bialystok, Poland.
  4. Bozena Mikoluc: Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Bialystok, Bialystok, Poland.
  5. Anna Stasiak-Barmuta: Department of Clinical Immunology, Medical University of Bialystok, Bialystok, Poland Email: samuelstroz92@gmail.com.

Abstract

Sixty patients with COVID-19 infection were categorized into mild and severe groups, and their immune response was analyzed using flow cytometry and complete blood count. An observed increase in immune activation parameters, notably a higher percentage of CD4 lymphocytes co-expressing CD69 and CD25 molecules, and enhanced activity of the macrophage-monocyte cell line was noted in the mild group. Although Group 2 (severe COVID) had fewer CD4 cells, significant migration and proliferation were evident, with increased CD4CD69, CD8 HLA-DR+, and CD8CD69 lymphocytes. The CD4 to CD8 ratio in Group 1 suggested potential autoimmune reactions, while Group 2 indicated potential immunosuppression from severe infection and employing immunosuppressive drugs. Additionally, Group 2 exhibited an increased neutrophil count, hinting at possible bacterial co-infection. Group 1 showed differences in CD4RO and CD8RA lymphocyte populations, implying that cellular immunity plays a role in developing efficient postinfectious immunity. This intimation suggests that vaccination might mitigate the severity of the coronavirus infection and prevent complications, including long-term COVID-19.

Keywords

References

  1. Cell. 2021 Feb 18;184(4):861-880 [PMID: 33497610]
  2. Front Pediatr. 2020 Dec 14;8:616622 [PMID: 33381482]
  3. Cell. 2020 Oct 1;183(1):158-168.e14 [PMID: 32979941]
  4. Viruses. 2021 Apr 18;13(4): [PMID: 33919537]
  5. J Physiol Pharmacol. 2021 Aug;72(4): [PMID: 34987123]
  6. J Med Life. 2023 Mar;16(3):447-450 [PMID: 37168295]
  7. Infez Med. 2021 Mar 1;29(1):20-36 [PMID: 33664170]
  8. Dtsch Arztebl Int. 2023 Jan 27;120(4):48-55 [PMID: 36633452]
  9. Lancet. 2020 Mar 28;395(10229):1033-1034 [PMID: 32192578]
  10. Ageing Res Rev. 2021 Jan;65:101205 [PMID: 33137510]
  11. Viruses. 2022 Aug 11;14(8): [PMID: 36016376]
  12. Cells. 2021 Dec 20;10(12): [PMID: 34944099]
  13. Front Immunol. 2022 Jun 10;13:886431 [PMID: 35757700]
  14. J Investig Med. 2022 Jan;70(1):61-67 [PMID: 34611034]
  15. Biosens Bioelectron. 2021 Feb 15;174:112830 [PMID: 33339696]
  16. Cell Death Differ. 2022 Jun;29(6):1107-1122 [PMID: 35581387]
  17. Infect Dis (Lond). 2021 Oct;53(10):737-754 [PMID: 34024217]
  18. Nat Commun. 2020 Jul 8;11(1):3410 [PMID: 32641700]
  19. Front Immunol. 2021 Mar 12;12:645013 [PMID: 33777042]
  20. Scand J Immunol. 2021 Apr;93(4):e12998 [PMID: 33190302]
  21. Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26:85-88 [PMID: 33236430]
  22. Prz Gastroenterol. 2020;15(4):301-308 [PMID: 33777269]
  23. Cell. 2022 Mar 3;185(5):881-895.e20 [PMID: 35216672]
  24. Przegl Epidemiol. 2022;76(3):287-295 [PMID: 36520039]
  25. Sci Transl Med. 2020 Jun 3;12(546): [PMID: 32493790]
  26. Pathogens. 2023 Jun 22;12(7): [PMID: 37513709]
  27. Cell Mol Immunol. 2020 May;17(5):541-543 [PMID: 32203186]
  28. Viruses. 2023 Jul 07;15(7): [PMID: 37515199]
  29. Immunogenetics. 2023 Jun;75(3):295-307 [PMID: 36752852]
  30. Sci Adv. 2021 Jul 30;7(31): [PMID: 34330709]

Word Cloud

Created with Highcharts 10.0.0GroupsevereCOVID-19infectionmildCD42patientsimmuneresponsecytometrycountlymphocytesincreasedCD81potentialimmunityvaccinationSixtycategorizedgroupsanalyzedusingflowcompletebloodobservedincreaseactivationparametersnotablyhigherpercentageco-expressingCD69CD25moleculesenhancedactivitymacrophage-monocytecelllinenotedgroupAlthoughCOVIDfewercellssignificantmigrationproliferationevidentCD4CD69HLA-DR+CD8CD69ratiosuggestedautoimmunereactionsindicatedimmunosuppressionemployingimmunosuppressivedrugsAdditionallyexhibitedneutrophilhintingpossiblebacterialco-infectionshoweddifferencesCD4ROCD8RAlymphocytepopulationsimplyingcellularplaysroledevelopingefficientpostinfectiousintimationsuggestsmightmitigateseveritycoronaviruspreventcomplicationsincludinglong-termImmunevariationT-cellsimmunologypost-COVIDsyndrome

Similar Articles

Cited By

No available data.